Pad­cev gets a shot at an­oth­er in­di­ca­tion — for in­va­sive blad­der can­cer — thanks to ini­tial da­ta read­out

Astel­las and Seagen’s con­tro­ver­sial nectin-4 ADC Pad­cev on­ly got ful­ly ap­proved last sum­mer, al­beit with a black box warn­ing against “se­vere and fa­tal cu­ta­neous ad­verse re­ac­tions.” But in spite of oth­er com­pa­nies look­ing to make a bet­ter Pad­cev, it looks like Seagen and Astel­las just might be able to take their drug in­to a new in­di­ca­tion.

The drug, orig­i­nal­ly get­ting the FDA’s full OK just last year for lo­cal­ly ad­vanced or metasta­t­ic urothe­lial can­cer, has been un­der study in Co­hort H of the Phase Ib/II EV-103 tri­al, which was look­ing at pa­tients with mus­cle-in­va­sive blad­der can­cer who were in­el­i­gi­ble for cis­platin-based chemother­a­py, ac­cord­ing to the com­pa­nies. Nor­mal­ly, the treat­ment for this type of can­cer is two-fold: cis­platin-based chemother­a­py plus surgery (re­moval of the blad­der and pelvic lymph node dis­sec­tion).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER